CpG 2006 treatment prolongs the survival of recipients of allogeneic TCD bone marrow challenged with AML cells early (day 36) after BMT.
Lethally irradiated B6 recipients were reconstituted with B10.BR TCD bone marrow (n = 9-10 per group). Cohorts of mice received no treatment, CpG 1585, or CpG 2006 ODNs. ODN treatment was initiated on day 20 and continued through day 65. On day 36, recipients were given C1498 cells at the indicated cell dose. Recipients treated with CpG 1585 or CpG 2006 had a prolonged survival compared with controls receiving 2 × 105 cells (P = .045 and .001, respectively). Recipients given CpG 1585 and C1498 cells at a dose of 2 × 105 cells survived for a shorter duration, whereas those receiving CpG 2006 survived for a comparable duration than controls receiving 10-fold fewer C1498 cells (2 × 104) (P = .049 and .34, respectively). On the basis of these data, CpG 2006 resulted in an approximate 10-fold reduction in tumorigenicity.
